A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo
NCT01803035
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
210
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-bullous Impetigo
Interventions
DRUG:
LTX-109 1 %
DRUG:
LTX-109 2 %
DRUG:
Placebo gel
Sponsor
Lytix Biopharma AS